Medical and Health

Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Market Growth 2019-2024


chemotherapy542.jpg

Chemotherapy-induced nausea and vomiting (CINV) is a common side-effect of many cancer treatments. Nausea and vomiting are two of the most feared cancer treatment-related side effects for cancer patients and their families.

The classification of Chemotherapy Induced Nausea and Vomiting (CINV) Drugs includes 5-HT3 Inhibitors, NK1 Inhibitors and others. The proportion of 5-HT3 Inhibitors in 2017 is about 62%, and the proportion of NK1 Inhibitors in 2017 is about 33%.

Chemotherapy Induced Nausea and Vomiting (CINV) Drugs are application for Highly Emetogenic Chemotherapy, Moderately Emetogenic Chemotherapy, Low Emetogenic Chemotherapy and others. The most of Chemotherapy Induced Nausea and Vomiting (CINV) Drugs is used for Moderately Emetogenic Chemotherapy, and the market share of that is about 52 % in 2017.

Download FREE Sample of this Report @ https://www.grandresearchstore.com/report-sample/global-chemotherapy-induced-nausea-vomiting-drugs-2019-2024-58

According to this study, over the next five years the Chemotherapy Induced Nausea and Vomiting (CINV) Drugs market will register a 5.9% CAGR in terms of revenue, the global market size will reach US$ 96 million by 2024, from US$ 72 million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in Chemotherapy Induced Nausea and Vomiting (CINV) Drugs business, shared in Chapter 3.

This report presents a comprehensive overview, market shares, and growth opportunities of Chemotherapy Induced Nausea and Vomiting (CINV) Drugs market by product type, application, key manufacturers and key regions and countries.

This study considers the Chemotherapy Induced Nausea and Vomiting (CINV) Drugs value and volume generated from the sales of the following segments:

Segmentation by product type: breakdown data from 2014 to 2019, in Section 2.3; and forecast to 2024 in section 11.7.

  • 5-HT3 Inhibitors
  • NK1 Inhibitors
  • Other

Segmentation by application: breakdown data from 2014 to 2019, in Section 2.4; and forecast to 2024 in section 11.8.

  • Highly Emetogenic Chemotherapy
  • Moderately Emetogenic Chemotherapy
  • Low Emetogenic Chemotherapy
  • Other

This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.

  • Americas
  • United States
  • Canada
  • Mexico
  • Brazil
  • APAC
  • China
  • Japan
  • Korea
  • Southeast Asia
  • India
  • Australia
  • Europe
  • Germany
  • France
  • UK
  • Italy
  • Russia
  • Spain
  • Middle East & Africa
  • Egypt
  • South Africa
  • Israel
  • Turkey
  • GCC Countries

The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report: Breakdown data in in Chapter 3.

  • Merck
  • Eisai
  • Mundipharma
  • Qilu Pharma
  • Teva
  • Novartis
  • Heron Therapeutics
  • Roche
  • Mylan
  • Tesaro

Research objectives:

  1. To study and analyze the global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs consumption (value & volume) by key regions/countries, product type and application, history data from 2014 to 2018, and forecast to 2024.
  2. To understand the structure of Chemotherapy Induced Nausea and Vomiting (CINV) Drugs market by identifying its various subsegments.
  3. Focuses on the key global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
  4. To analyze the Chemotherapy Induced Nausea and Vomiting (CINV) Drugs with respect to individual growth trends, future prospects, and their contribution to the total market.
  5. To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
  6. To project the consumption of Chemotherapy Induced Nausea and Vomiting (CINV) Drugs submarkets, with respect to key regions (along with their respective key countries).
  7. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
  8. To strategically profile the key players and comprehensively analyze their growth strategies.

Get the Complete Report & TOC @ https://www.grandresearchstore.com/life-sciences/global-chemotherapy-induced-nausea-vomiting-drugs-2019-2024-58

Table of content

1 Scope of the Report
1.1 Market Introduction
1.2 Research Objectives
1.3 Years Considered
1.4 Market Research Methodology
1.5 Economic Indicators
1.6 Currency Considered

2 Executive Summary
2.1 World Market Overview
2.1.1 Global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Consumption 2014–2024
2.1.2 Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Consumption CAGR by Region
2.2 Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Segment by Type
2.2.1 5-HT3 Inhibitors
2.2.2 NK1 Inhibitors
2.2.3 Other
2.3 Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Consumption by Type
2.3.1 Global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Consumption Market Share by Type (2014–2019)
2.3.2 Global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Revenue and Market Share by Type (2014–2019)
2.3.3 Global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Sale Price by Type (2014–2019)
2.4 Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Segment by Application
2.4.1 Highly Emetogenic Chemotherapy

CONTACT US:
276 5th Avenue, New York , NY 10001,United States
International: (+1) 646 781 7170 / +91 8087042414
Email: [email protected]

Follow Us On linkedin :- https://www.linkedin.com/company/grand-research-store/




Naresh Pawar - Grand Research Store



GR-Store has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.